Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges.
about
Can active components of licorice, glycyrrhizin and glycyrrhetinic acid, lick rheumatoid arthritis?Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data.Suppression of NFAT5-mediated Inflammation and Chronic Arthritis by Novel κB-binding Inhibitors.Pre-silencing of genes involved in the electron transport chain (ETC) pathway is associated with responsiveness to abatacept in rheumatoid arthritis.Green Tea Epigallocatechin-3-Gallate Suppresses Autoimmune Arthritis Through Indoleamine-2,3-Dioxygenase Expressing Dendritic Cells and the Nuclear Factor, Erythroid 2-Like 2 Antioxidant Pathway.Regulatory CD4+ T-Cell Subsets and Anti-Citrullinated Protein Antibody Repertoire: Potential Biomarkers for Arthritis Development in Seropositive Arthralgia Patients?Effects of Antitumor Necrosis Factor Therapy on Osteoprotegerin, Neopterin, and sRANKL Concentrations in Patients with Rheumatoid Arthritis.Serum leptin and serum leptin/serum leptin receptor ratio imbalance in obese rheumatoid arthritis patients positive for anti-cyclic citrullinated peptide antibodiesAnti-TNF certolizumab pegol induces antioxidant response in human monocytes via reverse signaling.Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritisGranulocyte macrophage colony-stimulating factor receptor α expression and its targeting in antigen-induced arthritis and inflammationEfficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events.Insights into Myeloid-Derived Suppressor Cells in Inflammatory Diseases.Filgotinib for the treatment of rheumatoid arthritis.Combination Therapy of PEG-HM-3 and Methotrexate Retards Adjuvant-Induced Arthritis.A systemic review and meta-analysis of the clinical efficacy and safety of total glucosides of peony combined with methotrexate in rheumatoid arthritis.Cytokines in rheumatoid arthritis - shaping the immunological landscape.Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster.Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry.Immunometabolism and autoimmunity.The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting.Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).Lack of association between MTHFR A1298C polymorphism and outcome of methotrexate treatment in rheumatoid arthritis patients: evidence from a systematic review and meta-analysis.The Challenge of Treating Early-Stage Rheumatoid Arthritis: The Contribution of Mixed Treatment Comparison to Choosing Appropriate Biologic Agents.Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial.Increased healthcare resource utilization in higher disease activity levels in initiators of TNF inhibitors among US rheumatoid arthritis patients.Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care.Inhibition of microRNA-34a ameliorates murine collagen-induced arthritis.Methotrexate and low-dose prednisolone downregulate osteoclast function by decreasing receptor activator of nuclear factor-κβ expression in monocytes from patients with early rheumatoid arthritis.Adherence to systemic therapies for immune-mediated inflammatory diseases in Lebanon: a physicians' survey from three medical specialties.The genetics of rheumatoid arthritis: new insights and implications.Bruton's Tyrosine Kinase Deficiency Inhibits Autoimmune Arthritis in Mice but Fails to Block Immune Complex-Mediated Inflammatory Arthritis.Harnessing Apoptotic Cell Clearance to Treat Autoimmune Arthritis.Feeding transgenic plants that express a tolerogenic fusion protein effectively protects against arthritis.Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors.Efficacy of golimumab for preventing large joint destruction in patients with rheumatoid arthritis as determined by the ARASHI score.Therapeutic Modulation of Plasmacytoid Dendritic Cells in Experimental Arthritis.Induction of Regulatory T Cells and Its Regulation with Insulin-like Growth Factor/Insulin-like Growth Factor Binding Protein-4 by Human Mesenchymal Stem Cells.
P2860
Q26779680-C54FAD4B-55EC-4B0C-8013-FC833C7C44F0Q31167447-686DF624-F9A1-42B5-9EDE-C60AC0B481C9Q33603679-31D09BD0-D763-4683-9456-0C4ADE1723A1Q33730446-F040176E-B6DA-403C-824C-4DA959854104Q36062141-11C062D9-FCCB-41B4-80EA-2830DD760647Q36120270-A9D623D2-58F0-4E44-B651-A0DA4D3F922FQ36245404-1EA29A9E-AC80-4BED-9721-664F3F3BAACDQ36304059-0C77E6D9-E33B-4243-AC24-71CAD4EF4083Q36639236-D6C851E0-818A-4C74-89D6-68FBBF9FCA11Q37133755-E3DBAEF6-FFA4-40B0-8BA5-FE9B42C837EAQ37466119-975B7FC8-7127-492A-A4A1-E980A1F77B89Q37653421-BEFBAD3B-2098-4291-9ACA-35784EA26D70Q38492085-CF39534F-8984-4E6A-8B98-E1BD5030AD1CQ38609755-6DFADFF2-09A0-4AA9-8C82-E97A06A345C7Q38650245-0E95E110-8B91-4B10-A178-3B5346FBD81AQ38658407-10ADCFC9-853C-4D29-878D-BC6D46D6F999Q38666239-40F3BC2B-A3DA-4419-97D1-80F20D7C61AAQ38837769-6D71C95F-967D-4AB0-ADCD-9B2B912B756BQ38907286-DF8D5902-2B26-4F95-BE1E-BFB8FB57A0B1Q38921982-775EC162-2B49-4CD8-A3F9-842F1DFF7047Q38937346-70F4FC97-E015-4124-AFC7-576B9553FF3FQ39029106-3FEEF147-C84B-486B-BE09-E09671A1109AQ39176539-A17BA242-42D1-4B5A-B1BF-95332ECE9D33Q39230189-614EC2EE-2DD1-41D2-87A6-CAEC94D9EC62Q39330126-9617EE3B-4B46-4CAB-8D3F-DDB5FC8F879AQ39976803-4BC27078-4E6D-4C69-B0E5-89D853F91455Q40353155-42392EA9-604F-428A-B4CC-FDB4E452C6E6Q40608716-4B926F67-8046-490B-9965-906F3BCF3664Q41106264-763B0E86-1092-4B9E-A171-4EE0AE8149BAQ41113739-C7F4CDCE-C017-4967-9616-5F1930C18A95Q41687198-9867D4BA-AD32-4AD7-8DCE-8590E0053FF5Q41816131-A185F256-8666-446A-9C73-197F1FCD32FBQ42336552-CBC4084E-1CAE-4589-BFE2-87C55CB76729Q46333548-0BE5956E-8419-4EB7-8CDC-AC1C1674ABC3Q47122664-5F660830-5331-4C1B-B59E-779610DA6397Q47641325-1FBD8EBD-2740-4ACA-B994-C16F223B3614Q47662522-2187DDA0-5635-4BE2-9227-96A0D0ED4C0BQ47879980-B69406FD-9168-4EFD-A992-E821C72DE7A8Q47990642-470F23AF-DEB1-45A8-83B2-F62CF550E2A9Q48099631-43B84FB5-A58B-4915-BCA1-FB9B1150A555
P2860
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges.
@en
type
label
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges.
@en
prefLabel
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges.
@en
P356
P1476
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges.
@en
P2093
Daniel Aletaha
P2888
P304
P356
10.1038/NRRHEUM.2015.8
P407
P577
2015-02-17T00:00:00Z
P6179
1008800983